IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

Phase 2

Terminated

• Conditions: Diabetes Mellitus, Type 1
• Interventions: Drug: IMCY-0098 1350 μg; Drug: IMCY-0098 450 μg; Drug: Placebo

• Registration Number: NCT04524949
• Lead Sponsor: Imcyse SA

Brief Summary

The IMPACT study is a study to test a new experimental drug, IMCY-0098, for the treatment of type 1 diabetes (T1D).

In most people with type 1 diabetes, the pancreas loses its ability to make insulin because some cells of the body's own immune system mistakenly attack and destroy the cells in the pancreas that produce insulin (islet beta-cells).

The study drug IMCY-0098 is being developed to stop the body's own immune system attacking and destroying the insulin-producing cells. When injected, it will induce new immune cells that will specifically destroy the bad immune cells responsible for the damage to the pancreas.

IMCY-0098 has previously been tested on recently diagnosed type 1 diabetes patients in the first clinical study between 2017 and 2019 to collect information on the safety of IMCY-0098. The next step is to test the best dose and the best number of injections that show the drug can give a benefit. Two doses of IMCY-0098 will be tested and they will be compared to a placebo. Safety information will also be collected during the study for all the participants.

Detailed Description

The main study will include 84 HLA DR4+ patients. In addition, up to 24 HLA DR4-/DR3+ patients will be included in a mechanistic substudy.

Study Timeline

• Study First Submitted: 2020-08-11
• Study First Submitted QC: 2020-08-21
• Study First Posted: 2020-08-24
• Study Start: 2020-12-29
• Primary Completion: 2024-01-26
• Study Completion: 2024-05-29
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-20
• Last Update Posted: 2024-06-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

1. Have given written informed consent.

2. Participants aged ≥ 18 years and < 45 years at the time of consent

3. Have a diagnosis of T1D within maximum 9 weeks at screening (date of the first insulin injection)

4. Must have at least one or more diabetes-related autoantibodies present at screening (GAD65, IA-2, or ZnT8)

5. Must have random C-peptide levels ≥ 200 pmol/L measured at screening

6. Must be Human Leukocyte Antigen (HLA) DR4 positive to participate in the main study OR HLA DR4 negative but HLA DR3 positive to participate in the substudy

7. Be willing to comply with intensive diabetes management

8. Be treated with insulin therapy in accordance with the local standard of care

9. Males with reproductive potential must agree to use adequate contraception up to 90 days after the completion of the last treatment. This includes:

   • Barrier contraception (condom and spermicide) or
   • True abstinence (where this is in accordance with the participants preferred and usual lifestyle)

10. All females must have a negative serum pregnancy test at screening. Women sexually active and of childbearing potential must agree to use a highly effective contraception method from screening up to 90 days after last treatment with the investigational product

11. (US ONLY) Have HbA1c levels ≤ 9.5% prior to randomization

Exclusion Criteria

1. Clinically significant abnormal full blood count (FBC), renal function or liver function at screening including

   1.1. Be immunodeficient or have any clinically significant chronic lymphopenia: Leukopenia (< 3,000 leukocytes /μL), neutropenia (<1,500 neutrophils/μL), lymphopenia (<800 lymphocytes/μL), or thrombocytopenia (<100,000 platelets/μL)

   1.2. Evidence of renal dysfunction with serum creatinine greater than 1.5 times the upper limit of normal OR (US ONLY) estimated Glomerular Filtration Rate (eGFR) calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) <90 mL/min per 1.73 m2 in absence of other signs of CKD or rapidly progressing renal disease

   1.3. Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3 times the upper limits of normal or (US ONLY) total bilirubin ≥ 2x Upper Limit of Normal (ULN) or Alkaline phosphatase ≥ 2x ULN. For participants presenting with values above ULN but below above threshold for these parameters, the underlying reason should be investigated by the site team to exclude liver disease. Patients for which a liver disease would be diagnosed will be excluded from the study.

   Participants with elevated unconjugated bilirubin (Gilbert's syndrome) are eligible if bilirubin is ≤ 3 times the upper limits of normal and hepatic enzymes and function are otherwise normal (AST/ALT/Alkaline phosphatase within ULN), and there is no evidence of hemolysis

2. Have signs or symptoms of serious active infection requiring IV antibiotics and/or hospitalization at study entry

3. Have signs or symptoms of active COVID infection or a positive COVID PCR test during the screening period

4. Have received any live attenuated vaccine within 3 months prior to the first planned administration of the study product (which includes, but is not limited to: oral poliomyelitis vaccine, measles-mumps-rubella vaccine, yellow fever vaccine, Japanese encephalitis vaccine, dengue vaccine, rotavirus vaccine, varicella vaccine, live-attenuated zoster vaccine, Bacillus Calmette-Guérin [BCG] vaccine, oral typhoid vaccine)

5. Be currently pregnant or lactating, or anticipate getting pregnant until at least 24 weeks after last study drug administration

6. Require the use of immunosuppressive agents including chronic use of systemic steroids. Topical, inhalational or intranasal corticosteroids are allowed

7. Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection

8. Presence of any uncontrolled disease (including uncontrolled autoimmune disease) or abnormal clinical laboratory results that may interfere with study conduct as judged by the investigator

9. History of, or current malignancy (except excised basal cell skin cancer)

10. Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control within 7 days prior to screening visit

11. Active participation in another T1D treatment study or any investigational intervention study in the previous 30 days or (US ONLY) received gene therapy in the past

12. Known hypersensitivity to any component of the drug product

13. CRO or Sponsor employees or employees under the direct supervision of the Investigator and/or involved directly in the study

14. Be diagnosed with Latent Autoimmune Diabetes in Adults (LADA)

15. (US ONLY) History or current evidence of hematologic condition that would make HbA1c uninterpretable including:

    15.1. Grade 1 anemia, defined as: Hemoglobin (Hb) < Lower Limit of Normal (LLN) - 10.0 g/dL or < LLN - 6.2 mmol/L or < LLN - 100 g/L

    15.2. Hemoglobinopathy, with the exception of sickle cell trait or thalassemia minor; or chronic or recurrent hemolysis

    15.3. Donation of blood or blood products to a blood bank, blood transfusion or participation in a clinical study requiring withdrawal of > 400 mL of blood during the 90 days prior to the Screening visit

    15.4. Significant iron deficiency anemia

    15.5. Heart malformations or Vaso-Occlusive Crisis (VOC) leading to increased turnover of erythrocytes

16. (US ONLY) Current evidence of hypertension defined as the mean (average) of Diastolic Blood Pressure (DBP) > 89 mm Hg or Systolic Blood Pressure (SBP) > 129 mm Hg based on 3 consecutive readings at least 2 minutes apart

17. (US ONLY) History or current evidence of active drug, chemical or alcohol dependency.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IMCY-0098, high dose	IMCY-0098 1350 μg	The dose B (Cohort 2) will consist of subcutaneous administrations of 1350 µg of the peptide in two separate injections of 675 µg each (500 µL each).
IMCY-0098, low dose	IMCY-0098 450 μg	The dose A (Cohort 1) will consist of subcutaneous administrations of 450 µg of the peptide in two separate injections of 225 µg each (500 µL each).
Placebo	Placebo	Participants randomized to placebo will receive subcutaneous administrations of identical volumes of placebo solution to maintain study blind.

Primary Outcome Measures

Name	Time	Method
Change in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) from baseline to 48 weeks between IMCY-0098 and placebo groups	From baseline to 48 weeks	The area under the stimulated C-peptide response curve over the first two hours of a MMTT

Secondary Outcome Measures

Name	Time	Method
Changes in stimulated C-peptide response during the first two hours of a MMTT for the two doses of IMCY-0098 versus placebo	From baseline to 24 months	The area under the stimulated C-peptide response curve over the first two hours of a MMTT
Difference in Dried Blood Spots (DBS) fasted C-peptide between treatment and placebo groups	From baseline to 48 weeks	DBS C-peptide measurements
Effects of each dose of IMCY-0098 on hypoglycaemic events	From baseline to 24 months	Number of treatment-emergent severe hypoglycaemic episodes
Effects of each dose of IMCY-0098 on daily total insulin dose	From baseline to 24 months	Change in insulin requirements as the daily total dose (three days average) in units per kg body weight
To evaluate the safety features of IMCY-0098 during treatment period	Up to 7 days after the last dose	Occurrence, intensity and relationship of any listed injection site and systemic AEs during a 7-day follow-up period after each dose
To evaluate the safety features of IMCY-0098 during the whole study duration	Up to 48 weeks	Occurrence, intensity and relationship of any unlisted injection site and AEs and occurrence and relationship of all SAEs and abnormality in physical examination, vital signs, 12-lead ECG
To evaluate the safety features of IMCY-0098 on lymphocytes ratio	Up to 48 weeks	Measure of CD4+/CD8+ lymphocytes ratio
Changes in DBS C-peptide measurements at each visit comparing each dose with placebo	From baseline to 24 months	The DBS C-peptide responses at each visit
Effects of each dose of IMCY-0098 on Continuous Glucose Monitoring (CGM) measures	From baseline to 24 months	CGM time in range (70-180 mg/dL, 3.9- 10.0 mmol/L), time above range (\>180 mg/dL, \>10.0 mmol/L), time below range (\<70 mg/dL, \< 3.9 mmol/L) during 10 days compared to the reference period (first 10 days after randomization)
Effects of each dose of IMCY-0098 on HbA1c	From baseline to 24 months	Change in HbA1c
Effects of each dose of IMCY-0098 on diabetic ketoacidosis (DKA) episodes	From baseline to 24 months	Number of treatment-emergent episodes of DKA
Impact of IMCY-0098 at each dose on autoantibodies against GAD65, IA 2, ZnT8 and insulin over time	From baseline to 24 months	Change in T1D associated autoantibodies (GADA, IAA, IA-2A and ZnT8A)

Trial Locations

Locations (29)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Barbara Davis Center; 🇺🇸 Aurora, Colorado, United States

University of Chicago; 🇺🇸 Chicago, Illinois, United States

Joslin Diabetes Center; 🇺🇸 Boston, Massachusetts, United States

Princess Alexandra Hospital; 🇦🇺 Brisbane, Australia

Royal Melbourne Hospital; 🇦🇺 Melbourne, Australia

St. Vincent's Hospital; 🇦🇺 Melbourne, Australia

Royal North Shore Hospital; 🇦🇺 Sydney, Australia

Université Libre de Bruxelles - Hôpital Erasme - ULB; 🇧🇪 Brussels, Belgium

UZ Brussels; 🇧🇪 Brussels, Belgium

Scroll for more (19 remaining)